General Statement of the International Society for the Study of Women's Sexual Health

The International Society for the Study of Women's Sexual Health (ISSWSH), the preeminent scientific organization focused on research, education, and clinical practice of women's sexuality, applauds the FDA's recent announcement of it's upcoming Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee on June 4, 2015.

The meeting culminates the prolonged development of flibanserin, a drug that could be the first approved medical treatment for distressing low sexual desire. Flibanserin offers a favorable safety and efficacy profile for the treatment of Hypoactive Sexual Desire Disorder in women. While we fully endorse the FDA's evidence-based review of the risks and benefits of this treatment, ISSWSH wishes to emphasize the significant unmet need for safe and effective medical therapies to address all women's sexual problems.

Save the Date

ISSWSH Fall Course 2020
Cancelled

ISSWSH Virtual Course 2020
November 6, 13, & 20, 2020  
Virtual
Stay tuned for updates

ISSWSH Annual Meeting 2021
March 4-7, 2021   210 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

Well if this isn't another good reason to have sex - delay menopause. https://t.co/cgeHZMfyzo ISSWSH
It's good to be alive now! 250 years ago, over one-fifth of Londoners had contracted syphilis by their 35th birthda… https://t.co/k0gRN0ZR0B ISSWSH
Wondering how to get your grove on? How to initiate sex https://t.co/X41FW5AlPS ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow Us

On Twitter
On Facebook
On Instagram